Enhancing monoclonal antibody stability during protein a chromatography using 2-methyl imidazolium dihydrogen

Ranjeet Desai1, Rahul Jaiswal2, Triveni Manchekar2

  • 1Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai 400019, India; Department of Biological Sciences and Biotechnology, Institute of Chemical Technology, Mumbai 400019, India.

PubMed

Insights

2-methyl imidazolium dihydrogen phosphate (2-MIDHP) significantly reduces monoclonal antibody (mAb) aggregation during Protein A purification at low pH. This additive enhances mAb stability without negatively impacting recovery or purity during bioprocessing.

Area of Science:

  • Biopharmaceutical Manufacturing
  • Protein Chemistry
  • Process Development

Background:

  • Monoclonal antibody (mAb) aggregation is a critical issue during downstream processing, potentially compromising product quality and efficacy.
  • Low pH conditions, often employed in Protein A chromatography and viral inactivation, can exacerbate mAb instability and promote aggregation.
  • Developing strategies to mitigate aggregation under these stressed conditions is crucial for robust biomanufacturing.

Purpose of the Study:

  • To investigate the impact of 2-methyl imidazolium dihydrogen phosphate (2-MIDHP) on mAb aggregation during Protein A purification at low pH.
  • To evaluate the effect of 2-MIDHP on mAb recovery, host cell protein (HCP) clearance, and Protein A leaching.
  • To assess the influence of 2-MIDHP on mAb thermal stability and structural integrity.

Main Methods:

  • Size-exclusion high-performance liquid chromatography (SE-HPLC) and dynamic light scattering (DLS) were used to quantify mAb aggregation.
  • Differential scanning calorimetry (DSC) was employed to analyze mAb thermal stability.
  • Circular dichroism (CD) and fluorescence spectroscopy were utilized to probe mAb structural changes.

Main Results:

  • 2-MIDHP demonstrated a concentration-dependent protective effect against mAb aggregation at pH 3.0, reducing aggregation from 3.8% to 0.56% with increasing concentrations.
  • No significant adverse effects were observed on mAb recovery, HCP clearance, or Protein A leaching.
  • DSC, CD, and fluorescence spectroscopy indicated that 2-MIDHP enhanced mAb thermal stability and maintained protein structure without causing denaturation.

Conclusions:

  • 2-MIDHP effectively mitigates mAb aggregation during low pH Protein A purification, likely by stabilizing the antibody structure.
  • The use of 2-MIDHP presents a promising strategy for improving the robustness and efficiency of mAb purification processes.
  • These findings contribute to enhancing the quality and yield of therapeutic monoclonal antibodies.

Related Concept Videos

Affinity Chromatography01:03

Affinity Chromatography

Affinity chromatography is a powerful technique extensively utilized for separating and purifying specific biomolecules from complex mixtures. It capitalizes on the highly selective binding between an analyte and its counterpart, such as antibody-antigen interactions. The counterpart is immobilized on the stationary phase, forming an affinity column. The stationary phase typically consists of solid support, such as agarose or porous glass beads, immobilizing the affinity ligand. The mobile...
573
Immunoprecipitation01:20

Immunoprecipitation

Immunoprecipitation, or IP, is a widely used technique that employs protein-antibody interactions to isolate proteins or protein complexes in their native state for studying protein-protein interactions, quaternary structures, or supramolecular complexes. Various modifications of the technique, including chromatin IP, cross-linking IP, and fluorescence IP, are commonly used.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation, also known as ChIP, is used to study protein-DNA or...
5.4K
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.2K